# Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine

> **NCT00995332** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Bergen** · enrollment: 36 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Cytarabine, all-trans retinoic acid, valproic acid

## Key facts

- **NCT ID:** NCT00995332
- **Lead sponsor:** University of Bergen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00995332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00995332, "Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00995332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*